TABLE 1.
Baseline demographics and clinical characteristics.
| Characteristics | Participants (n = 11) |
|---|---|
| Demographic | |
| Age, mean ± SD, years | 61.6 ± 13.6 |
| Female, n (%) | 6 (54.5%) |
| Married, n (%) | 7 (63.6%) |
| Tertiary education, n (%) | 2 (18.2%) |
| Current employed, n (%) | 4 (36.4%) |
| Current smoker, n (%) | 0 (0%) |
| IPAQ MET‐min/week, median (IQR) a | 516 (363–1292) |
| Met PA Guidelines, n (%) | 3 (27.3%) |
| Clinical | |
| Body weight, mean ± SD, kg | 84.0 ± 18.9 |
| BMI, mean ± SD, kg.m−2 | 28.4 ± 7.6 |
| BMI categories, n (%) | |
| Normal weight (BMI < 25 kg.m−2) | 4 (36.4%) |
| Overweight (BMI ≥ 25– < 30 kg.m−2) | 5 (45.6%) |
| Obese (BMI ≥ 30 kg.m−2) | 2 (18.2%) |
| Time since diagnosis, median (IQR), months | 11 (7–60) |
| Time since treatment began, median (IQR), months | 7 (0–9) |
| Cancer stage, n (%) | |
| Stage III | 1 (9.1%) |
| Stage IV | 10 (90.9%) |
| Metastasis sites, n (%) | |
| Lung | 6 (54.5%) |
| Liver | 3 (27.3%) |
| Lymph nodes | 2 (18.2%) |
| Brain | 2 (18.2%) |
| Gastric lymphoma | 1 (9.1%) |
| Pancreas | 1 (9.1%) |
| Spine | 1 (9.1%) |
| Number of medications, median (IQR) | 1.0 (0.0–3.0) |
| Comorbidities, n (%) | |
| Hypertension | 3 (27.3%) |
| Hypercholesterolemia | 4 (36.4%) |
| Diabetes | 2 (18.2%) |
| Depression | 1 (9.1%) |
| Previous treatment, n (%) | |
| Surgery | 9 (81.8%) |
| Radiation therapy | 3 (27.3%) |
| Chemotherapy | 1 (9.1%) |
| Immunotherapy | 4 (36.4%) |
| BRAF/MEK inhibitor therapy | 1 (9.1%) |
| Checkpoint inhibitor type, n (%) | |
| PD‐1 | 7 (63.6%) |
| CTLA‐4 | 2 (18.2%) |
| PD‐1/CTLA‐4 combination | 2 (18.2%) |
Abbreviations: BMI, body mass index; BRAF/MEK, v‐Raf murine sarcoma viral oncogene homologue B/mitogen‐activated protein kinase; CTLA‐4, cytotoxic T‐lymphocyte‐associated protein 4; IPAQ, International Physical Activity Questionnaire; IQR, interquartile range; MET, metabolic equivalent minutes; PA, physical activity; PD‐1, programmed cell death protein 1; SD, standard deviation.
a
n = 10.